To include your compound in the COVID-19 Resource Center, submit it here.

No advisory panel meeting planned for Ultragenyx's burosumab in adult and pediatric XLH

On Nov. 1, Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Kyowa Hakko Kirin Co. Ltd.

Read the full 134 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE